Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Diamond

Showing results (331-340 of 344) with videos related to

Pageof 35
Sort By:
Oncotarget|July 8, 2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancerTodd M Pitts, Erica L Bradshaw-Pierce, Stacey M Bagby, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Cancers|January 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna R Schreiber, Jodi A Kagihara, Bradley R Corr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesDaniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
The New England Journal of Medicine|February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
NPJ Breast Cancer|October 5, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerAnthony D Elias, Alyse W Staley, Monica Fornier, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 1, 1996
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS TreatmentM S Simberkoff, P M Hartigan, J D Hamilton, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Sustaining wakefulness: Brainstem connectivity in human consciousnessBrian L Edlow, Mark Olchanyi, Holly J Freeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.
Pageof 35

Showing results (331-340 of 344) with videos related to

Sort By:
Pageof 35
Oncotarget|July 8, 2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancerTodd M Pitts, Erica L Bradshaw-Pierce, Stacey M Bagby, et al.
Molecular Cancer Therapeutics|September 7, 2019
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast CancerAnna Capasso, Stacey M Bagby, Kyrie L Dailey, et al.
Cancers|January 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna R Schreiber, Jodi A Kagihara, Bradley R Corr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesDaniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
The New England Journal of Medicine|February 21, 2019
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Linda T Vahdat, et al.
NPJ Breast Cancer|October 5, 2024
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerAnthony D Elias, Alyse W Staley, Monica Fornier, et al.
Molecular Cancer Therapeutics|December 30, 2021
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid TumorsJennifer R Diamond, Todd M Pitts, Dana Ungermannova, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 1, 1996
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS TreatmentM S Simberkoff, P M Hartigan, J D Hamilton, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Sustaining wakefulness: Brainstem connectivity in human consciousnessBrian L Edlow, Mark Olchanyi, Holly J Freeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Ingrid A Mayer, Jennifer R Diamond, et al.
Pageof 35